D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
News Channel Nebraska14d
Circadian Rhythm Sleep Treatment Market is Projected to Reach a Size of US$ 1.23 Billion at a CAGR of 4.7% by 2034
Leading Players Driving Innovation in the Circadian Rhythm Sleep Treatment Market Key players in that circadian rhythm sleep treatment market are Vanda Pharmaceuticals, Inc., Akeda Pharmaceutical ...
FOX 40 WICZ TV14d
Circadian Rhythm Sleep Treatment Market is Projected to Reach a Size of US$ 1.23 Billion at a CAGR of 4.7% by 2034
Leading Players Driving Innovation in the Circadian Rhythm Sleep Treatment Market Key players in that circadian rhythm sleep treatment market are Vanda Pharmaceuticals, Inc., Akeda Pharmaceutical ...
ETF Daily News18d
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com
NASDAQ:VNDA opened at $4.36 on Monday. The company has a market cap of $254.23 million, a P/E ratio of -15.57 and a beta of 0.77. Vanda Pharmaceuticals has a 52-week low of $3.46 and a 52-week ...
Nasdaq18d
Vanda Pharmaceuticals Inc. Common Stock (VNDA) Earnings
Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...
AOL22d
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate
Also Read: Over 200% Stock Upside – Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst In September, the FDA issued a Complete Response Letter to the company.
Indiatimes23d
Japanese pharma Takeda launches innovation centre, eyes to onboard AI-driven talent
Japanese pharmaceutical company Takeda inaugurated its first Innovation Capability Centre (ICC) in Bengaluru, marking its debut in Asia. The ICC aims to employ 750 professionals, including software ...